Inogen Reports Q3 Revenue of $92.4 Million and Net Loss of $5.3 Million
Reuters
Nov 05, 2025
Inogen Reports Q3 Revenue of $92.4 Million and Net Loss of $5.3 Million
Inogen Inc. reported third quarter 2025 revenue of $92.4 million, a 4.0% increase year-over-year. The company posted a GAAP net loss of $5.3 million and an adjusted net loss of $0.5 million, compared to a GAAP net loss of $6.0 million and an adjusted net loss of $2.6 million in the prior year period. Adjusted EBITDA was $2.3 million, marking the third consecutive quarter of positive adjusted EBITDA. Operating cash flow was $2.2 million, with cash, cash equivalents, marketable securities, and restricted cash totaling $124.5 million at quarter-end and no debt outstanding. Inogen reiterated its full year 2025 revenue outlook of $354 million to $357 million and raised adjusted EBITDA guidance to approximately $2.0 million. The company also initiated a limited market release of the Simeox airway clearance device in the United States during the quarter.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inogen Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251105832834) on November 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.